The Burden of Age-Related Macular Degeneration: Results of a Cohort Study in Two French Referral Centres
The DOI matches its Crossref record; 40 of the 41 references it cites were found in a registry or an index.
Abstract
Objective To describe the economic impact of age-related macular degeneration (AMD) and to assess its medical and non-medical costs.Design and settings An observational study was carried out in 105 patients in two French centres in a sample of 105 French patients. All consecutive patients, consulting during a 3-week period, were included provided they were 60 years of age or older and they presented an exudative form of AMD with a distant visual acuity in the best eye < or = 20/40. Data collected included clinical items, treatment modalities, medical follow-up, transport costs, impact of AMD on living conditions and welfare payments related to visual impairment. Costs were presented in 2000 values.Perspective General payer perspective (Social Security, private health insurance and patient).Results Mean age was 79.3 years and ranged from 62.8-95 years. Average length of disease evolution was 3.5 years. During a 3-month period, patients had a mean of 2.6 visits to the ophthalmologist. Thirty percent of the patients used vascular medications and 72.4% had been previously treated by laser photocoagulation. Only 10% had benefited from visual rehabilitation. Annual AMD cost per patient was 3660.29 euros (EUR) [95% CI: 2881.92-4438.62]. Half of these annual costs were medical costs. Other major cost components were home help costs EUR904.91 [95% CI: 478.88-1330.94] and transport costs for care EUR542.73 [95% CI: 146.31-939.14]. Non-medical costs were significantly higher for patients with more severe disease.Conclusions The economic argument that costs are higher in patients with the lowest visual acuity emphasises the necessity of early detection and treatment of patients with AMD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Nine studies [34, 37–43, 45] reported direct non-medical costs per patient per annum, ranging from $688 to $15,418 (Fig. 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [45]
In the citing paper
“Often, direct non-medical costs increased in line with the severity of vision impairment [37, 41, 42, 45] and in certain instances exceeded direct medical costs in patients with more severe vision impairment [42, 45].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [45]
In the citing paper
“Often, direct non-medical costs increased in line with the severity of vision impairment [37, 41, 42, 45] and in certain instances exceeded direct medical costs in patients with more severe vision impairment [42, 45].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [45]
In the citing paper
“While annual direct non-medical costs were uniformly lower than direct medical costs in three studies [34, 39, 40] reporting both types of costs, they were higher in other cases [37, 41–43, 45].”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [45]
In the citing paper
“The most frequent resources accounted for within direct non-medical costs were formal care [34, 38–43, 45] and assistive technologies [34, 37–39, 41–43, 45], followed by transportation [34, 37–39, 42, 45] and subsidies [40–43] (Table 3).”
From The economic impact of retinal diseases for which gene therapy is emerging: a systematic literature review (2025) · cites this paper as [45]
Citations
Cites
Prevalence of age-related maculopathy
Klein, R., Klein, B. E. K., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31871-8 · Cited by 1,845 · cited 1×
“These estimations are relatively concordant with results of epidemiological studies conducted in other countries.[6-16] Estimations essentially vary according to the definition of AMD and to the selected age groups.”
ResultPrevalence of age-related maculopathy in Australia
Mitchell, P., Smith, W., Attebo, K., & Wang, J. J. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)30846-9 · Cited by 1,062
The Prevalence of Age-related Maculopathy in the Rotterdam Study
Vingerling, J. R., Dielemans, I., Hofman, A., Grobbee, D. E., Hijmering, M., Kramer, C. F. L., & de Jong, P. T. V. M. (1995) · Ophthalmology · doi:10.1016/s0161-6420(95)31034-2 · Cited by 815
KAHN, H. A., LEIBOWITZ, H. M., GANLEY, J. P., KINI, M. M., COLTON, T., NICKERSON, R. S., & DAWBER, T. R. (1977) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a112428 · Cited by 752
Age-related macular degeneration
Bressler, N. M., Bressler, S. B., & Fine, S. L. (1988) · Survey of Ophthalmology · doi:10.1016/0039-6257(88)90052-5 · Cited by 681
Bressler, N. M. (2001) · Cited by 599
(1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080090044025 · Cited by 495
Age-Related Macular Degeneration
Fine, S. L., Berger, J. W., Maguire, M. G., & Ho, A. C. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002173420707 · Cited by 418
Cataracts and Macular Degeneration in Older Americans
Klein, B. E., & Klein, R. (1982) · Archives of Ophthalmology · doi:10.1001/archopht.1982.01030030573002 · Cited by 276
Research works printed but not linked: 3
- Arnold, 1999, Clin Evid, 2, 247
- Gibson, 1985, Trans Ophthalmol Soc UK, 104, 196
- Wu, 1987, Jpn J Ophthalmol, 31, 349
Cited by
Quality of life in age-related macular degeneration: a review of the literature
Mitchell, J., & Bradley, C. (2006) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-4-97 · Cited by 304
Cost-of-Illness Studies: A Review of Current Methods
Akobundu, E., Ju, J., Blatt, L., & Mullins, C. D. (2006) · PharmacoEconomics · doi:10.2165/00019053-200624090-00005 · Cited by 279
Weeks, D. E., Conley, Y. P., Tsai, H.-J., Mah, T. S., Schmidt, S., Postel, E. A., Agarwal, A., Haines, J. L., Pericak-Vance, M. A., Rosenfeld, P. J., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/422476 · Cited by 195
Kaarniranta, K., Pawlowska, E., Szczepanska, J., Jablkowska, A., & Blasiak, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102374 · Cited by 194
Evaluation of Quality of Life for Patients With Glaucoma
Spaeth, G., Walt, J., & Keener, J. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.07.075 · Cited by 185
Metadata
- Authors
- Bonastre, J., Le Pen, C., Soubrane, G., & Quentel, G.
- Affiliations
- Hôpital Intercommunal de Créteil (FR)
- Centre Ophtalmologique d'Imagerie et de Laser (FR)
- ORCID
- Bonastre, Julia
- Venue
- PharmacoEconomics
- Published
- 2003
- Volume
- 21
- Issue
- 3
- Pages
- 181-190
- ISSN
- 1170-7690 (ISSN-L)
- OpenAlex
- W1996994847
- Cited by
- 65
- References
- 41
- Citations by year
- 2025: 1 · 2023: 2 · 2022: 1 · 2021: 1 · 2019: 3 · 2018: 1 · 2017: 1 · 2016: 2 · 2015: 3 · 2014: 3 · 2013: 1 · 2012: 1
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- PharmacoEconomics (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Novartis Pharma
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Visual Impairment Studies
- Keywords
- age-related macular degeneration, exudative AMD, economic burden, health care costs, non-medical costs, transportation costs, visual impairment, welfare benefits, visual rehabilitation, laser photocoagulation, vascular therapy, visual acuity, early detection
- MeSH terms
- Aged, Aged, 80 and over, Audiovisual Aids, France, Humans, Macular Degeneration, Middle Aged, Visual Acuity, Cohort Studies, Cost of Illness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Burden of Age-Related Macular Degeneration: Results of a Cohort Study in Two French Referral Centres. https://app.cochat.ai/papers/10.2165/00019053-200321030-00003
- The paper
- Bonastre, J., Le Pen, C., Soubrane, G., & Quentel, G. (2003). The Burden of Age-Related Macular Degeneration: Results of a Cohort Study in Two French Referral Centres. PharmacoEconomics. https://doi.org/10.2165/00019053-200321030-00003
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.